Download Files:
Acyclovir
$66 – $158
Products Details
Product Description
– Acyclovir (Aciclovir) is a potent, orally active antiviral agent. Acyclovir has antiherpetic activity with IC50 values of 0.85 μM and 0.86 μM for HSV-1 and HSV-2, respectively. Acyclovir induces cell cycle perturbation and apoptosis. Acyclovir prevents bacterial infections during induction therapy for acute leukaemia[1][2][3][4].
Web ID
– HY-17422
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– COVID-19-anti-virus
Molecular Formula
– C8H11N5O3
References
– [1]Benedetti S, et, al. Acyclovir induces cell cycle perturbation and apoptosis in Jurkat leukemia cells, and enhances chemotherapeutic drug cytotoxicity. Life Sci. 2018 Dec 15;215:80-85.|[2]Suzuki M, et, al. Synergistic antiviral activity of acyclovir and vidarabine against herpes simplex virus types 1 and 2 and varicella-zoster virus. Antiviral Res. 2006 Nov;72(2):157-61.|[3]Li Z, et, al. Acyclovir treatment of skin lesions results in immune deviation in mice infected cutaneously with herpes simplex virus. Antivir Chem Chemother. 1999 Sep;10(5):251-7.|[4]Lönnqvist B, et, al. Oral acyclovir as prophylaxis for bacterial infections during induction therapy for acute leukaemia in adults. The Leukemia Group of Middle Sweden. Support Care Cancer. 1993 May;1(3):139-44.
CAS Number
– 59277-89-3
Molecular Weight
– 225.20
Compound Purity
– 99.34
SMILES
– O=C1NC(N)=NC2=C1N=CN2COCCO
Clinical Information
– Launched
Research Area
– Cancer; Infection
Solubility
– DMSO : ≥ 50 mg/mL
Target
– Antibiotic;Apoptosis;Bacterial;HSV
Isoform
– HSV-1;HSV-2
Pathway
– Anti-infection;Apoptosis
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
